NLS Pharmaceutics (NCEL) Competitors

NLS Pharmaceutics logo
$2.68 -0.07 (-2.55%)
As of 02:53 PM Eastern

NCEL vs. KVAC, CRDF, XBIT, PDSB, and BOLD

Should you buy NLS Pharmaceutics stock or one of its competitors? NLS Pharmaceutics's main competitors and comparable companies include Keen Vision Acquisition (KVAC), Cardiff Oncology (CRDF), XBiotech (XBIT), PDS Biotechnology (PDSB), and Boundless Bio (BOLD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does NLS Pharmaceutics compare to Keen Vision Acquisition?

NLS Pharmaceutics (NASDAQ:NCEL) and Keen Vision Acquisition (NASDAQ:KVAC) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, earnings, profitability, dividends, analyst recommendations, valuation, media sentiment and institutional ownership.

51.7% of Keen Vision Acquisition shares are owned by institutional investors. 16.4% of NLS Pharmaceutics shares are owned by company insiders. Comparatively, 80.2% of Keen Vision Acquisition shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Company Net Margins Return on Equity Return on Assets
NLS PharmaceuticsN/A N/A N/A
Keen Vision Acquisition N/A N/A N/A

NLS Pharmaceutics currently has a consensus price target of $23.00, indicating a potential upside of 758.21%. Given NLS Pharmaceutics' higher possible upside, analysts clearly believe NLS Pharmaceutics is more favorable than Keen Vision Acquisition.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NLS Pharmaceutics
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Keen Vision Acquisition
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

In the previous week, NLS Pharmaceutics' average media sentiment score of 1.82 beat Keen Vision Acquisition's score of 0.00 indicating that NLS Pharmaceutics is being referred to more favorably in the media.

Company Overall Sentiment
NLS Pharmaceutics Very Positive
Keen Vision Acquisition Neutral

NLS Pharmaceutics has a beta of 1.09, meaning that its stock price is 9% more volatile than the broader market. Comparatively, Keen Vision Acquisition has a beta of -0.04, meaning that its stock price is 104% less volatile than the broader market.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NLS PharmaceuticsN/AN/A-$8.30MN/AN/A
Keen Vision AcquisitionN/AN/AN/AN/AN/A

Summary

NLS Pharmaceutics beats Keen Vision Acquisition on 4 of the 6 factors compared between the two stocks.

How does NLS Pharmaceutics compare to Cardiff Oncology?

NLS Pharmaceutics (NASDAQ:NCEL) and Cardiff Oncology (NASDAQ:CRDF) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, risk, earnings, valuation, media sentiment and analyst recommendations.

16.3% of Cardiff Oncology shares are held by institutional investors. 16.4% of NLS Pharmaceutics shares are held by insiders. Comparatively, 8.8% of Cardiff Oncology shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

NLS Pharmaceutics has a net margin of 0.00% compared to Cardiff Oncology's net margin of -6,736.49%. NLS Pharmaceutics' return on equity of 0.00% beat Cardiff Oncology's return on equity.

Company Net Margins Return on Equity Return on Assets
NLS PharmaceuticsN/A N/A N/A
Cardiff Oncology -6,736.49%-111.80%-81.51%

NLS Pharmaceutics has higher earnings, but lower revenue than Cardiff Oncology.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NLS PharmaceuticsN/AN/A-$8.30MN/AN/A
Cardiff Oncology$590K111.60-$45.85M-$0.55N/A

In the previous week, Cardiff Oncology had 7 more articles in the media than NLS Pharmaceutics. MarketBeat recorded 7 mentions for Cardiff Oncology and 0 mentions for NLS Pharmaceutics. NLS Pharmaceutics' average media sentiment score of 1.82 beat Cardiff Oncology's score of 0.71 indicating that NLS Pharmaceutics is being referred to more favorably in the media.

Company Overall Sentiment
NLS Pharmaceutics Very Positive
Cardiff Oncology Positive

NLS Pharmaceutics has a beta of 1.09, indicating that its stock price is 9% more volatile than the broader market. Comparatively, Cardiff Oncology has a beta of 1.57, indicating that its stock price is 57% more volatile than the broader market.

NLS Pharmaceutics currently has a consensus price target of $23.00, suggesting a potential upside of 758.21%. Cardiff Oncology has a consensus price target of $7.50, suggesting a potential upside of 786.11%. Given Cardiff Oncology's stronger consensus rating and higher probable upside, analysts plainly believe Cardiff Oncology is more favorable than NLS Pharmaceutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NLS Pharmaceutics
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Cardiff Oncology
1 Sell rating(s)
3 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.29

Summary

Cardiff Oncology beats NLS Pharmaceutics on 7 of the 13 factors compared between the two stocks.

How does NLS Pharmaceutics compare to XBiotech?

NLS Pharmaceutics (NASDAQ:NCEL) and XBiotech (NASDAQ:XBIT) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, risk, analyst recommendations, dividends, valuation and profitability.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NLS PharmaceuticsN/AN/A-$8.30MN/AN/A
XBiotechN/AN/A-$45.54M-$1.43N/A

NLS Pharmaceutics' return on equity of 0.00% beat XBiotech's return on equity.

Company Net Margins Return on Equity Return on Assets
NLS PharmaceuticsN/A N/A N/A
XBiotech N/A -33.03%-31.57%

55.7% of XBiotech shares are held by institutional investors. 16.4% of NLS Pharmaceutics shares are held by insiders. Comparatively, 21.1% of XBiotech shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

NLS Pharmaceutics has a beta of 1.09, suggesting that its share price is 9% more volatile than the broader market. Comparatively, XBiotech has a beta of 0.76, suggesting that its share price is 24% less volatile than the broader market.

In the previous week, XBiotech had 1 more articles in the media than NLS Pharmaceutics. MarketBeat recorded 1 mentions for XBiotech and 0 mentions for NLS Pharmaceutics. NLS Pharmaceutics' average media sentiment score of 1.82 beat XBiotech's score of -0.61 indicating that NLS Pharmaceutics is being referred to more favorably in the media.

Company Overall Sentiment
NLS Pharmaceutics Very Positive
XBiotech Negative

NLS Pharmaceutics presently has a consensus price target of $23.00, indicating a potential upside of 758.21%. Given NLS Pharmaceutics' stronger consensus rating and higher probable upside, analysts clearly believe NLS Pharmaceutics is more favorable than XBiotech.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NLS Pharmaceutics
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
XBiotech
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Summary

NLS Pharmaceutics beats XBiotech on 8 of the 11 factors compared between the two stocks.

How does NLS Pharmaceutics compare to PDS Biotechnology?

PDS Biotechnology (NASDAQ:PDSB) and NLS Pharmaceutics (NASDAQ:NCEL) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, valuation, profitability, risk and dividends.

PDS Biotechnology presently has a consensus price target of $9.50, indicating a potential upside of 962.88%. NLS Pharmaceutics has a consensus price target of $23.00, indicating a potential upside of 758.21%. Given PDS Biotechnology's stronger consensus rating and higher probable upside, research analysts clearly believe PDS Biotechnology is more favorable than NLS Pharmaceutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
PDS Biotechnology
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33
NLS Pharmaceutics
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

26.8% of PDS Biotechnology shares are owned by institutional investors. 8.4% of PDS Biotechnology shares are owned by company insiders. Comparatively, 16.4% of NLS Pharmaceutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PDS BiotechnologyN/AN/A-$34.50M-$0.56N/A
NLS PharmaceuticsN/AN/A-$8.30MN/AN/A

NLS Pharmaceutics' return on equity of 0.00% beat PDS Biotechnology's return on equity.

Company Net Margins Return on Equity Return on Assets
PDS BiotechnologyN/A -1,012.57% -151.42%
NLS Pharmaceutics N/A N/A N/A

In the previous week, PDS Biotechnology had 2 more articles in the media than NLS Pharmaceutics. MarketBeat recorded 2 mentions for PDS Biotechnology and 0 mentions for NLS Pharmaceutics. NLS Pharmaceutics' average media sentiment score of 1.82 beat PDS Biotechnology's score of -0.70 indicating that NLS Pharmaceutics is being referred to more favorably in the news media.

Company Overall Sentiment
PDS Biotechnology Negative
NLS Pharmaceutics Very Positive

PDS Biotechnology has a beta of 1.16, indicating that its stock price is 16% more volatile than the broader market. Comparatively, NLS Pharmaceutics has a beta of 1.09, indicating that its stock price is 9% more volatile than the broader market.

Summary

PDS Biotechnology beats NLS Pharmaceutics on 6 of the 11 factors compared between the two stocks.

How does NLS Pharmaceutics compare to Boundless Bio?

Boundless Bio (NASDAQ:BOLD) and NLS Pharmaceutics (NASDAQ:NCEL) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, dividends, profitability, analyst recommendations, media sentiment, earnings and valuation.

NLS Pharmaceutics' return on equity of 0.00% beat Boundless Bio's return on equity.

Company Net Margins Return on Equity Return on Assets
Boundless BioN/A -70.98% -50.99%
NLS Pharmaceutics N/A N/A N/A

NLS Pharmaceutics has a consensus price target of $23.00, indicating a potential upside of 758.21%. Given NLS Pharmaceutics' stronger consensus rating and higher probable upside, analysts clearly believe NLS Pharmaceutics is more favorable than Boundless Bio.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Boundless Bio
2 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
NLS Pharmaceutics
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

In the previous week, Boundless Bio had 2 more articles in the media than NLS Pharmaceutics. MarketBeat recorded 2 mentions for Boundless Bio and 0 mentions for NLS Pharmaceutics. NLS Pharmaceutics' average media sentiment score of 1.82 beat Boundless Bio's score of 1.29 indicating that NLS Pharmaceutics is being referred to more favorably in the news media.

Company Overall Sentiment
Boundless Bio Positive
NLS Pharmaceutics Very Positive

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Boundless BioN/AN/A-$58.20M-$2.47N/A
NLS PharmaceuticsN/AN/A-$8.30MN/AN/A

Boundless Bio has a beta of 0.02, suggesting that its stock price is 98% less volatile than the broader market. Comparatively, NLS Pharmaceutics has a beta of 1.09, suggesting that its stock price is 9% more volatile than the broader market.

Summary

NLS Pharmaceutics beats Boundless Bio on 8 of the 9 factors compared between the two stocks.

Get NLS Pharmaceutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for NCEL and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NCEL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NCEL vs. The Competition

MetricNLS PharmaceuticsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$15.88M$4.06B$7.82B$11.74B
Dividend YieldN/A3.63%2.47%4.47%
P/E RatioN/A25.6832.7626.82
Price / SalesN/A16.068.565.70
Price / CashN/A22.9521.0121.90
Price / Book1.694.184.463.72
Net Income-$8.30M-$24.15M$3.52B$393.10M
7 Day Performance-6.29%-7.25%-5.47%-4.73%
1 Month Performance7.20%-5.98%-4.57%-7.14%
1 Year Performance-22.99%-7.72%-1.79%-7.51%

NLS Pharmaceutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NCEL
NLS Pharmaceutics
2.3369 of 5 stars
$2.68
-2.5%
$23.00
+758.2%
-21.2%$15.88MN/AN/A6
KVAC
Keen Vision Acquisition
N/A$11.51
flat
N/AN/A$63.37MN/AN/AN/A
CRDF
Cardiff Oncology
1.9476 of 5 stars
$0.77
-3.7%
$7.50
+880.0%
-60.2%$59.53M$590KN/A31
XBIT
XBiotech
1.0017 of 5 stars
$1.95
-1.0%
N/A-29.9%$59.45MN/AN/A87
PDSB
PDS Biotechnology
1.953 of 5 stars
$1.02
-1.0%
$9.50
+831.4%
+9.9%$57.09MN/AN/A21

Related Companies and Tools


This page (NASDAQ:NCEL) was last updated on 11/17/2026 by MarketBeat.com Staff.
From Our Partners